Pyrotinib combined with CDK4/6 inhibitor in HER2‐positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients
Zuhua Chen(Peking University Cancer Hospital), Lin Shen(Peking University)
Cited by 31
Related Papers
Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K‐Akt signaling in gastric cancer
|Cancer Medicine|2019|318
Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial
|BMC Medicine|2022|76
Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer
|Journal of Hematology & Oncology|2018|44
From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression
|Frontiers in Pharmacology|2022|25